Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
- DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m.
- 09/19/2024
|
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
- DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024. Webcast The webcasted fireside chat will take place at 12:15 p.m.
- 08/08/2024
|
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
- Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products.
- 08/06/2024
|
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
- Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan Term loan maturity extended to June 12, 2028 Extension of Revolving Credit Facility increases potential borrowing capacity DENVER, CO / ACCESSWIRE / June 18, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company. In addition, the Company received $3.5 million of additional capital through the exercise of warrants from its June 2023 equity financing, a portion of which was used to pay down the term loan indebtedness.
- 06/18/2024
|
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode.
- 05/15/2024
|
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
- Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business $19.8 million cash balance at March 31, 2024 Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter.
- 05/15/2024
|
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
- DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m.
- 05/08/2024
|
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
- Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
- 04/03/2024
|
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
- Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
- 02/14/2024
|
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
- Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023 $19.5 million cash balance at December 31, 2023 Company to host conference call and webcast today, February 14, 2024 at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
- 02/14/2024
|
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
- DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m.
- 02/07/2024
|
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
- DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024. Company Webcast The webcasted fireside chat will take place at 11:45am ET on Thursday, February 1, 2024.
- 01/23/2024
|
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
- Webcasted presentation to take place at 1:10pm ET DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023. Mr. Disbrow will conduct a presentation and subsequently open the floor to questions.
- 11/30/2023
|
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki.
- 11/14/2023
|
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
- Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash balance at September 30, 2023 Company to host conference call today at 4:30pm ET DENVER, CO / ACCESSWIRE / November 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the first quarter of fiscal 2024 ended September 30, 2023. Q1 2024 Commercial Highlights (3 months ending September 30, 2023) Total net revenue was $22.1 million, compared to $27.7 million.
- 11/14/2023
|
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
- Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced, for the third year in a row, it was included on the Deloitte Technology Fast 500™, ranking 118th among North American companies and 23rd among life sciences companies. Now in its 29th year, the Deloitte Technology Fast 500 recognizes the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
- 11/08/2023
|
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
- DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.
- 11/07/2023
|
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
- U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product Margins DENVER, CO / ACCESSWIRE / October 26, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Cotempla to the Company's third-party manufacturer and follows a similar achievement for Adzenys XR- ODT® ("Adzenys") which received PAS approval in April 2023.
- 10/26/2023
|
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
- ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://investors.aytubio.com/ or https://wsw.com/webcast/lytham9/aytu/2072440.
- 10/09/2023
|
Best Penny Stocks? 4 Hot Stocks With News This Week
- What do you consider the best penny stocks? Are they the ones exploding higher within a single session?
- 09/28/2023
|
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call.
- 09/27/2023
|
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
- Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023 Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / September 27, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023. Q4 2023 Commercial Highlights (3 months ending June 30, 2023) Total net revenue was $30.7 million, an increase of 12% from the $27.4 million in net revenue in the year-ago quarter and the highest in company history.
- 09/27/2023
|
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
- ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.
- 09/21/2023
|
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
- ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles. Management will present on Wednesday, October 4th at 10:00am PT.
- 09/13/2023
|
Aytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Naz Rahman - Maxim Group, LLC Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call.
- 05/11/2023
|
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
- ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 4:30 pm ET, to review the results.
- 05/04/2023
|
Aytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2023 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Vernon Bernardino - H.C. Wainwright Operator Greetings.
- 02/21/2023
|
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
- ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for the quarter ended December 31, 2022, after the market close today, Tuesday, February 21, 2023. The Company has also scheduled a conference call for today, Tuesday, February 21, 2023, at 5:00 pm ET, to review the results.
- 02/21/2023
|
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
- ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, after the market close on Tuesday, February 14, 2023. The Company has scheduled a conference call that same day, Tuesday, February 14, 2023, at 4:30 pm ET, to review the results.
- 02/07/2023
|
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
- ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 9:00 am ET on Tuesday, January 31, 2023, on the Company's website at https://irdirect.net/AYTU or at https://wsw.com/webcast/lytham7/aytu/2069810.
- 01/24/2023
|
4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- 01/13/2023
|
Aytu BioPharma, Inc. (AYTU) Q1 2023 Earnings Call Transcript
- Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2023 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call. At this time, all participants are placed on a listen-only mode and the floor for questions and comments after the presentation.
- 11/14/2022
|
Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 5:12 PM ET Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2022 Earnings Conference Call September 27, 2022, 16:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Mark Oki - CFO Robert Blum - Lytham Partners Conference Call Participants Vernon Bernardino - H.C. Wainwright Sumant Kulkarni - Canaccord Operator Good afternoon everyone and welcome to Aytu BioPharma's Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.
- 09/27/2022
|
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
- ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal year ended June 30, 2022, after the market close on Tuesday, September 27, 2022. The Company has scheduled a conference call that same day, Tuesday, September 27, 2022, at 4:30 pm ET, to review the results.
- 09/20/2022
|
Aytu BioPharma to Participate in September 2022 Investor Conferences
- ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.
- 08/24/2022
|
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
- Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/19/2022
|
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
- Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
- 02/18/2022
|
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
- The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
- 12/09/2021
|
Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
- Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
- 11/15/2021
|
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
- ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the first quarter fiscal 2022 and provide an overview of its business and growth strategy.
- 11/08/2021
|
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Aytu BioPharma Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/04/2021
|
ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors
- NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are a stockholder of Aytu BioPharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/aytu /.
- 10/04/2021
|
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
- (This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23 rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m.
- 09/30/2021
|
Recap: Aytu BioPharma Q4 Earnings
- Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
- 09/29/2021
|
Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript
- Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript
- 09/27/2021
|
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
- ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on September 27, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the fourth quarter and fiscal year 2021 and provide an overview of its business and growth strategy.
- 09/23/2021
|
Aytu BioPharma to Present at Upcoming September Investor Conferences
- ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23 rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m.
- 09/07/2021
|
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
- ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the Healight™ endotracheal catheter technology was published in the peer reviewed journal Photodiagnosis and Photodynamics Therapy. "These latest in vitro findings continue to build upon the body of scientific evidence supporting the potential of this UVA platform technology and may help to explain the observed effects of Healight in SARS-CoV-2.
- 07/27/2021
|
Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options
- Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.
- 07/07/2021
|
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
- Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients ENGLEWOOD, CO / ACCESSWIRE / June 28, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A (UVA) light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy. The UVA light catheter technology utilized in this study is the basis of Aytu BioPharma's Healight™ medical device which has been exclusively licensed worldwide for all endotracheal and nasopharyngeal applications.
- 06/28/2021
|
Technical Levels To Watch In Aytu BioPharma Stock
- Aytu BioPharma Inc. (NASDAQ: AYTU) shares were rallying Monday after retail traders were able to push the stock higher. The stock has traded on above-average volume with 7.6 million shares traded so far — over 1,000% its average volume over the last 100 days.
- 06/21/2021
|
What's Next For Aytu BioPharma Stock As It Gaps Up To Resistance?
- Aytu BioPharma Inc. (NASDAQ: AYTU) shares saw a gap up Tuesday morning as retail traders tried to push the stock higher. The stock saw a sizable premarket move and opened at $6.15, but has since fallen back near the $5.70 price level.
- 06/08/2021
|
Aytu BioPharma to Present at Upcoming June Investor Conferences
- ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies Global Healthcare Conference: A live virtual presentation will occur on Tuesday, June 1, 2021 at 3:30 p.m. ET. Webcast Link: https://wsw.com/webcast/jeff174/aytu/1881765 Raymond James Human Health Innovations Conference: A live virtual presentation will occur on Wednesday, June 23, 2021 at 12:40 p.m.
- 05/25/2021
|
Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
- Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
- 05/17/2021
|
Recap: Aytu BioPharma Q3 Earnings
- Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to ($0.43), which missed the estimate of ($0.31).
- 05/17/2021
|
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- - Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline - - Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year - - Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET - ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights.
- 05/17/2021
|
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
- ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used in the Healight™ UVA endotracheal catheter technology was published in BioRxiv, an online archive for health science manuscripts that are not yet peer reviewed. The manuscript titled "Ultraviolet-A light increases mitochondrial anti-viral signaling protein via cell-cell communication" concluded that UVA light increases the expression of mitochondrial antiviral-signaling (MAVS) protein within cells, and the results suggest that this transmission of an increase in intracellular MAVS involves cell-to-cell communication.
- 05/12/2021
|
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
- ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.
- 05/10/2021
|
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
- Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline Company to host conference call today at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) from Rumpus Therapeutics (Rumpus), a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases. vEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus.
- 04/12/2021
|
5 Stocks to Buy on New Analyst Coverage
- Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
- 04/07/2021
|
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
- ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations, supporting clinical development and commercialization, and raising capital within the life sciences sector.
- 04/05/2021
|
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
- Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation (ASP)(ASPCF) whereby Acerus will acquire all remaining rights to Natesto in the United States from Aytu. In consideration, Aytu will receive $7.5M in cash from Acerus, which is payable in $250,000 monthly payments over 30 months.
- 04/01/2021
|
10 Reddit Penny Stocks Seeing the Most Chatter Today
- Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
- 03/22/2021
|
Aytu BioScience Announces Close of Merger with Neos Therapeutics
- $100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth P. Hecht and Gerald McLaughlin have joined the Aytu BioPharma board of directors ENGLEWOOD, CO / ACCESSWIRE / March 22, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the closing of its merger with Neos Therapeutics (previously trading on Nasdaq under "NEOS").
- 03/22/2021
|
Why Did Aytu Biosciences Gap Up Today? Technical Levels To Watch
- Aytu Biosciences Inc. (NASDAQ: AYTU) shares gapped up Thursday morning. The price jump is speculatively from the meetings the company is having about the proposed merger with Neos Therapeutics Inc. (NASDAQ: NEOS).
- 03/18/2021
|
Merger News: Why NEOS Stock and AYTU Stock Are Climbing Today
- NEOS stock holders will get AYTU stock in this no-cash merger transaction. Today's vote has the support of two proxy advisory firms.
- 03/18/2021
|
Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?
- Neos Therapeutics Inc (NASDAQ: NEOS) and Aytu BioScience Inc (NASDAQ: AYTU) shares are rising today in the premarket session, though there is no news on both companies. The investors are reacting to the companies' respective special meetings of stockholders related to the proposed merger between Aytu and Neos that will happen today.
- 03/18/2021
|
Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?
- Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 03/12/2021
|
Aytu BioScience Stock Is Trading Higher After Healight Therapy Shows Improved Outcome In COVID-19 Patients
- Aytu BioScience Inc (NASDAQ: AYTU) rises sharply in the premarket after first-in-human data with endotracheal UVA light catheter therapy show positive outcome in SARS-CoV-2 patients. Known as Healight, light catheter therapy is an investigational medical device being studied as a prospective treatment for COVID-19 and other respiratory infections.
- 03/09/2021
|
AYTU Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of Aytu Bioscience Inc (NASDAQ: AYTU) increased by over 15% pre-market. This is why it happened.
- 03/09/2021
|
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
- Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients ENGLEWOOD, CO / ACCESSWIRE / March 8, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released. The pre-print publication titled "Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study" concluded that endotracheal UVA light treatment was associated with a significant reduction of SARS-CoV-2 viral load and improvement in WHO clinical severity scores.
- 03/08/2021
|
Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
- Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
- 02/12/2021
|
Play Stocks With Rising P/E to Realize Solid Gains
- Bet on these top-ranked stocks with rising P/E to realize outsized gains.
- 02/08/2021
|
Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
- Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant upside potential and numerous exciting catalysts to be announced that could drive significant share price value in the very near future.
- 12/31/2020
|
Why These 4 Health Care Stocks Are Moving Today
- Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products.
- 12/28/2020
|
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
- First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight™ ultraviolet A light catheter technology. This single center, U.S.-based study evaluated the safety and proof of principle of the Healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with COVID-19.
- 12/28/2020
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.
- NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU). Stockholders will...
- 12/10/2020
|
Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
- The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. Gilead Snaps Up Germany Drug Company In $1B Deal: Large-cap pharma Gilead announced Thursday an agreement to acquire German biotech MYR, which focuses on therapeutics for chronic hepatitis delta virus, or HDV, for an upfront payment of 1.15 billion euros ($1.39 billion) in cash, payable upon closing of the transaction, and 300 million euros ($363 million) in potential future milestone payments.
- 12/10/2020
|
Neos Therapeutics News: Why NEOS Stock Is Soaring Today
- Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soaring Today appeared first on InvestorPlace.
- 12/10/2020
|
Where Do Hedge Funds Stand On Aytu BioScience, Inc. (AYTU)?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September 30th, 2020. In this article we are going to take a look at smart money sentiment towards Aytu BioScience, Inc. (NASDAQ:AYTU).
- 11/26/2020
|
Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative
- Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and PerformanceENGLEWOOD, CO / ACCESSWIRE / August 19, 2020 / Aytu BioScience, Inc.
- 08/19/2020
|
Is Aytu BioScience (NASDAQ:AYTU) Using Debt In A Risky Way?
- The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- 08/17/2020
|
Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study
- Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
- 08/17/2020
|
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q2 2020 Results - Earnings Call Transcript
- Acerus Pharmaceuticals Corporation (OTCQB:ASPCF) Q2 2020 Earnings Conference Call August 11, 2020, 10:00 AM ET Company Participants Bob Motz - CFO Ed Gudaitis - President and CEO Conference Call Participants Presentation Operator Good morning, ladies and gentlemen, and welcome to the Second Quarter 2020 Conference Call for Acerus Pharmaceuticals Corporation.
- 08/11/2020
|
Acerus Reports Fiscal 2020 Second Quarter Financial Results
- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month
- 08/11/2020
|
NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403
- Cancer Targeted Technology receives $1.44M in year 2 of SBIR Phase IIB grant to fund clinical trial of new PSMA-targeted therapeutic agent, CTT1403.
- 08/07/2020
|
LD Micro Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
- Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
- 08/04/2020
|
Aytu Bioscience, Inc. (AYTU) Outpaces Stock Market Gains: What You Should Know
- Aytu Bioscience, Inc. (AYTU) closed at $1.39 in the latest trading session, marking a +1.46% move from the prior day.
- 07/31/2020
|
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration
- Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMistENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc.
- 07/30/2020
|
COVID-19 IgG/IgM Rapid Test Cassette Distributed by Aytu BioScience Featured in Business Insider Article
- Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.
- 07/27/2020
|
Aytu BioScience Announces Expansion of NATESTO(R) U.S. Commercial Team
- Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / ACCESSWIRE / July 20, 2020 / Aytu BioScience, Inc.
- 07/20/2020
|
Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States
- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription p
- 07/20/2020
|
Sperm Banks - Global Market Trajectory & Analytics to 2027 with Profiles of 43 Competitors - ResearchAndMarkets.com
|
Aytu Bioscience (NASDAQ:AYTU) Shares Gap Up to $1.34
- Aytu Bioscience Inc (NASDAQ:AYTU) gapped up prior to trading on Friday . The stock had previously closed at $1.27, but opened at $1.34. Aytu Bioscience shares last traded at $1.37, with a volume of 9,286,390 shares changing hands. AYTU has been the subject of a number of research reports. Zacks Investment Research upgraded shares of […]
- 07/12/2020
|
Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States
- ENGLEWOOD, CO / ACCESSWIRE / July 10, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced today that the Company has signed a distribution agreement with Apollo Med Innovations, Inc. ("Apollo") to distribute the COVID-19 IgG/IgM Rapid Test Cassette to Apollo's network of over 1,000 practices across the United States. This distribution relationship expands the Company's coverage of clinician and professional customers to a large network of medical clinics, clinical laboratories, and wellness centers.
- 07/10/2020
|
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?
- Is (AYTU) Outperforming Other Medical Stocks This Year?
- 07/07/2020
|
Singapore stock watch: SIA, ComfortDelGro, CapitaLand, Ascendas Reit, Halcyon Agri
- SINGAPORE (THE BUSINESS TIMES) - The following companies saw new developments that may affect trading of their securities on Monday (June 29):. Read more at straitstimes.com.
- 06/29/2020
|
Stocks to watch: SIA, ComfortDelGro, CapitaLand, Ascendas Reit, Halcyon Agri
- THE following companies saw new developments that may affect trading of their securities on Monday: Read more at The Business Times.
- 06/29/2020
|
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy
- Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 06/25/2020
|
ASLAN Pharmaceuticals (ASLN) Looks Good: Stock Adds 8.7% in Session
- ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- 06/25/2020
|
Edited Transcript of AYTU earnings conference call or presentation 14-May-20 8:30pm GMT
- Q3 2020 Aytu BioScience Inc Earnings Call
- 06/25/2020
|
Aclaris Therapeutics (NASDAQ:ACRS) versus Aytu Bioscience (NASDAQ:AYTU) Financial Analysis
- Aclaris Therapeutics (NASDAQ:ACRS) and Aytu Bioscience (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Insider & Institutional Ownership 81.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, […]
- 06/24/2020
|
Hot Stock Evaluation- Aytu BioScience, Inc. (NASDAQ:AYTU)’s E-P-S strolling at -1.54, - Stocks Equity
- On Monday, shares of Aytu BioScience, Inc. (NASDAQ:AYTU) reached at $1.51 price level during last trade its distance from 20 days simple moving average was [...]
- 06/22/2020
|
Global Female Technology Market (2019 to 2030) - Featuring Bloomlife, CORA & Flo Health Among Others - ResearchAndMarkets.com
|
Aytu BioScience: The Next Arbor Pharmaceuticals?
- Between December 2019 and March 2020, Aytu had issued almost 100M shares which diluted existing shareholders 81%. Throughout this dilution, Aytu has grown reven
- 06/18/2020
|
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?
- Is (AYTU) Outperforming Other Medical Stocks This Year?
- 06/18/2020
|
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
- bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
- 06/15/2020
|
Global Imaging Agents Industry (2019 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com
|
Why Aytu BioScience (AYTU) Stock Might be a Great Pick
- Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/12/2020
|
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
- Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.
- 06/11/2020
|
Milestone Pharmaceuticals (MIST) Looks Good: Stock Adds 6.5% in Session
- Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 06/10/2020
|
Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%
- Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
- 06/09/2020
|
IDEAYA (IDYA) Looks Good: Stock Adds 10.2% in Session
- IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
- 06/09/2020
|
Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company’s Licensed COVID-19 IgG/IgM Rapid Test
- National Cancer Institute's (NCI) analysis of COVID-19 IgG/IgM Rapid Test Cassette Reported 100% Combined Sensitivity, and 97.5% Combined Specificity for the Lateral Flow Immunoassay ENGLEWOOD, CO / ACCESSWIRE ...
- 06/09/2020
|
Aytu BioScience Set to Join Russell 3000(R) Index
- ENGLEWOOD, CO / ACCESSWIRE / June 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant ...
- 06/08/2020
|
Is Aytu BioScience, Inc. (AYTU) A Good Stock To Buy?
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/05/2020
|
Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States
- ENGLEWOOD, CO / ACCESSWIRE / June 3, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that, as of July 1, 2020, Express Scripts, Inc., ("Express Scripts"), one of the leading pharmacy benefit managers (PBMs) in the United States, has elected to make Natesto® (testosterone nasal gel) a preferred brand on its National Preferred Drug List. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "This improved formulary placement by Express Scripts is a significant development for Natesto enabling greater patient access in the U.S. The addition of Natesto as Preferred on the Express Scripts National Preferred formulary will enable significantly increased access to Natesto for the 13 million U.S. men diagnosed with hypogonadism."
- 06/03/2020
|
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
- Is (AYTU) Outperforming Other Medical Stocks This Year?
- 06/02/2020
|
Russia Says It's Developing UV Light Therapy to Treat Coronavirus
- Scientists warned about the dangers of UV radiation after U.S. President Trump suggested it as treatment.
- 06/02/2020
|
Aytu BioScience Announces $15 Million Debt Retirement
- Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase Company's Debt Reduced to Approximately $1 Million ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 ...
- 06/01/2020
|
Aytu BioScience Announces Emergency Use Authorization of COVID-19 IgG/IgM Rapid Test
- Fourth FDA Emergency Use Authorization of a COVID-19 IgG/IgM Lateral Flow Rapid Test 1.4 Million Rapid Tests Available for Distribution at Company's Warehouse ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 ...
- 06/01/2020
|
Coronavirus Impact on Healthcare Acquired Infection Market
- May 26, 2020 (Heraldkeepers) --
New York, May 26, 2020: You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 05/26/2020
|
Aytu BioScience, Inc. (NASDAQ:AYTU): Is Breakeven Near?
- Aytu BioScience, Inc.'s (NASDAQ:AYTU): Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing...
- 05/16/2020
|
Aytu BioScience, Inc.'s (AYTU) CEO Joshua Disbrow on Q3 2020 Results - Earnings Call Transcript
- Aytu BioScience, Inc. (NASDAQ:AYTU) Q3 2020 Results Earnings Conference Call May 14, 2020, 04:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO
- 05/15/2020
|
Aytu Bioscience, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
- Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/14/2020
|
Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results
- Company Reports Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Year-over-Year $62.5 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at ...
- 05/14/2020
|
Acerus Pharmaceuticals' (ASPCF) CEO Ed Gudaitis on Q1 2020 Results - Earnings Call Transcript
- Acerus Pharmaceuticals Corporation (OTCQB:ASPCF) Q1 2020 Earnings Conference Call May 12, 2020 8:30 AM ET Company Participants Bob Motz – Chief Financial Office
- 05/12/2020
|
Acerus Reports First Quarter 2020 Financial Results
- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month perio
- 05/12/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Aytu Bioscience Inc (AYTU) Outpaces Stock Market Gains: What You Should Know
- Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.
- 05/07/2020
|
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update
- ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant ...
- 05/07/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aytu BioSciences, Inc. - AYTU
- Pomerantz LLP is investigating claims on behalf of investors of Aytu BioSciences, Inc. (“Aytu” or the “Company”) (NASDAQ: AYTU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Aytu and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/05/2020
|
Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2020
|
Column: How Cedars-Sinai got sucked into the battle over Trump's claim of a COVID-19 treatment
- Cedars-Sinai is embroiled in a political battle over Trump's remarks on a potential virus treatment.
- 05/01/2020
|
How Are Coronavirus Trades Changing?
- The market's still WILD and coronavirus is at the center of it all. So how are coronavirus trades changing and how can you adapt?
- 04/30/2020
|
RDS.A, LYG among premarket losers
- Chesapeake Energy (NYSE:CHK) -43% after preparing bankruptcy filing.On Deck Capital (NYSE:ONDK) -19% on Q1 earnings.Capricor Therapeutics (NASDAQ:CAPR) -16%.Capstead Mortgage (NYSE:CMO) -13% on Q1 ear
- 04/30/2020
|
FDA Expediting Accelerated Development of Novel Therapies for COVID-19
- The U.S. Federal government is working closely with companies and researchers to find treatments and vaccines to overcome the global health crisis. The FDA has been cutting red tape and has launched new programs that relax certain time consuming regulations while still assuring the efficacy and safety
- 04/28/2020
|
96 Biggest Movers From Yesterday
- Gainers
Naked Brand Group Limited (NASDAQ: NAKD) shares climbed 60.8% to close at $0.78 on Monday after climbing 8% on Friday.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares...
- 04/28/2020
|
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?
- On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
- 04/27/2020
|
AMRN, EPR among top gainers
- Axsome Therapeutics (NASDAQ:AXSM) +44% as Axsome's lead candidate successful in Alzheimer's study.Avadel Pharmaceuticals plc (NASDAQ:AVDL) +34% on positive data on lead drug.Yield10 Bioscience (NASDAQ
- 04/27/2020
|
CHK, BYND among premarket gainers
- Mesoblast (NASDAQ:MESO) +119% as cell therapy shows significant benefit in COVID-19 patients.Medigus (NASDAQ:MDGS) +73% on COVID-19 plan.Pluristem Therapeutics (NASDAQ:PSTI) +20% on €50 capital raise.
- 04/24/2020
|
LVS, INO among premarket gainers
- CounterPath (NASDAQ:CPAH) +91% on Q4 update.Borqs Technologies (NASDAQ:BRQS) +22% on launching mobile smart tracking cloud solution.Immunomedics (NASDAQ:IMMU) +34% as FDA gave approval to its treatmen
- 04/23/2020
|
Aytu BioScience: A Corona-Portunist With 40%+ Downside
- Aytu BioSciences' shares have unjustifiably risen on the company's announcement of a licensing deal to distribute a COVID-19 test in the U.S. Aytu is selling th
- 04/20/2020
|
EXEL, TNK among premarket gainers
- Avalon GloboCare (NASDAQ:AVCO) +44% on advancing immunotherapeutic program towards combatting cytokine storm associated with COVID-19 lung damage and mortality.Safe-T Group Ltd (NASDAQ:SFET) +41% on r
- 04/20/2020
|
Unapproved Chinese coronavirus antibody tests being used in at least 2 states
- Some Chinese-made COVID-19 antibody tests being used in the U.S. were not approved by China's FDA. China has now barred their export.
- 04/17/2020
|
California doctor charged after claiming 'cure' for COVID-19
- A San Diego doctor who operates a medical spa has been charged with mail fraud for allegedly offering what he claimed was a cure and preventative treatment for the coronavirus illness COVID-19. There is no cure.
- 04/17/2020
|
CEOs on Trump's council say they weren't aware of plan to reopen economy
- Here are the latest coronavirus updates from around the world.
- 04/17/2020
|
Star-crossed neighbors find love in Italy in the pandemic
- Here are the latest coronavirus updates from around the world.
- 04/17/2020
|
Michael Cohen to be released from prison early
- Here are the latest coronavirus updates from around the world.
- 04/17/2020
|
Boeing to resume plane production in Washington state
- Aircraft manufacturer Boeing says it will begin a phased approach to resuming plane production at its Seattle-area facilities next week, although with extra safeguards amid the coronavirus epidemic.
- 04/17/2020
|
Unapproved Chinese coronavirus antibody tests being used in at least 2 states
- Some Chinese-made COVID-19 antibody tests being used in the U.S. were not approved by China's FDA. China has now barred their export.
- 04/16/2020
|
ANI FDA Application, And Other News: The Good, Bad And Ugly Of Biopharma
- ANIP submitted a prior approval supplement to the FDA. La Jolla's GIAPREZA to be used as COVID-19 treatment, stock shoots up. Aytu BioScience reported the launc
- 04/16/2020
|
Aytu BioScience Stock: Developments in Denver
- Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.
- 04/16/2020
|
APHA, AAL among premarket gainers
- Applied DNA Sciences (NASDAQ:APDN) +61% on advancement of COVID-19 vaccine candidates.Comstock Holding Companies (NASDAQ:CHCI) +45% on FY results.BOQI International Medical (NASDAQ:BIMI) +25% on formi
- 04/15/2020
|
These Medical ETFs & Stocks Deserve a Salute on Health Day
- The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
- 04/07/2020
|
XpresSpa pursues COVID-19 screening, testing at U.S. airports XSPA;DGX;AYTU;HSIC
- XpresSpa pursues COVID-19 screening, testing at U.S. airports XSPA DGX AYTU HSIC
- 04/03/2020
|
Top Ranked Momentum Stocks to Buy for April 3rd
- Top Ranked Momentum Stocks to Buy for April 3rd
- 04/03/2020
|
Top Ranked Momentum Stocks to Buy for April 3rd
- Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd
- 04/03/2020
|
Shipping begins for Aytu rapid blood test - COVID-19 updates
- Aytu BioScience (NASDAQ:AYTU) has begun shipping its rapid antibody blood test for COVID-19. Shares up 8% premarket.Stryker (NYSE:SYK) has developed a low-cost limited-release emergency response bed f
- 04/03/2020
|
Top Ranked Momentum Stocks to Buy for April 2nd
- Top Ranked Momentum Stocks to Buy for April 2nd
- 04/02/2020
|
Top Ranked Momentum Stocks to Buy for April 2nd
- Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd
- 04/02/2020
|
LK, CCL among premarket losers
- Luckin Coffee (NASDAQ:LK) -84% on fraud finding.Golar LNG Partners (NASDAQ:GMLP) -55% on dividend cut.Safe-T Group (NASDAQ:SFET) -28% after pricing direct offering.Dynatronics (NASDAQ:DYNT) -22% on gu
- 04/02/2020
|
NVAX, INSG among premarket gainers
- InflaRx N.V. (NASDAQ:IFRX) +54% with doses of first COVID-19 with IFX-1.Qumu (NASDAQ:QUMU) +39%.Chembio Diagnostics (NASDAQ:CEMI) +26% on launching rapid COVID-19 blood test.Safe-T Group (NASDAQ:SFET)
- 04/01/2020
|
Aytu: A One-Trick Play
- Aytu BioScience is a one-trick play around COVID-19 test distribution. The company does not likely have additional value in its product pipeline and is likely t
- 04/01/2020
|
FDA OKs emergency use of 2-minute coronavirus test
- Doing all it can to get quick COVID-19 tests into the field in the U.S., the FDA has signed off on Emergency Use Authorization for Bodysphere's qualitative (yes or no answer) blood test that detects t
- 03/31/2020
|
AMRN, CCL among premarket losers
- Amarin (NASDAQ:AMRN) -68% after court decision on Vascepa.Delphi Technologies (NYSE:DLPH) -27% on cost reductions.SuperCom (NASDAQ:SPCB) -22%.ElectroCore (NASDAQ:ECOR) -20%.Carnival (NYSE:CCL) -14% af
- 03/31/2020
|
Warning: Quick coronavirus blood test could spell trouble, experts say
- “No test is perfect,” counters Little Saigon doctor who has administered 200 tests and ordered 12,000 more.
- 03/27/2020
|
Coronavirus Scare Supports These Biotech ETFs & Stocks
- Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
- 03/24/2020
|
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
- The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
- 03/24/2020
|
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
- The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
- 03/24/2020
|
Coronavirus Scare Supports These Biotech ETFs & Stocks
- Stocks Analysis by Zacks Investment Research covering: S&P 500, Dow Jones Industrial Average, Gilead Sciences Inc, Biogen Inc. Read Zacks Investment Research's latest article on Investing.com
- 03/24/2020
|
Coronavirus Test Kit Demand to Drive These 3 Stocks
- Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
- 03/23/2020
|
BMY, TLRY among premarket gainers
- Waitr Holdings (NASDAQ:WTRH) +51% on expanding into Grocery Delivery.Innate Pharma S.A. (NASDAQ:IPHA) +34% on potential use of cancer drug for Covid-19.DCP Midstream, LP (NYSE:DCP) +31% on cutting 202
- 03/23/2020
|
RDS.A, NRZ among premarket gainers
- Waitr Holdings (NASDAQ:WTRH) +70% as few consumer stocks are performing well during the rough road ahead.iFresh (NASDAQ:IFMK) +56%.Biomerica (NASDAQ:BMRA) +52% on advancement of rapid coronavirus test
- 03/19/2020
|
CERC: Data from CDG-FIRST Trial Upcoming…
- By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Financial Update On March 11, 2020, Cerecor, Inc. (NASDAQ:CERC) announced financial results for the fourth quarter and full year 2019. The company reported net product revenue of $6.7 million for 2019 compared to $6.6 million for 2018
- 03/19/2020
|
DOW, REGN among premarket gainers
- BioNTech SE (NASDAQ:BNTX) +55% on teaming up with Pfizer teams to develop COVID-19 vaccine.Co-Diagnostics (NASDAQ:CODX) +45% as FDA to allow states to authorize coronavirus tests.Neon Therapeutics (NA
- 03/17/2020
|
FDA to allow states to authorize coronavirus tests
- Aimed at ramping up testing capacity in the U.S., the FDA will now allow individual states to authorize the use of laboratory-developed tests by qualified in-state labs for the coronavirus causing the
- 03/17/2020
|
The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals
- The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus. I-Mab ADR (NASDAQ: IMAB)The Shanghai-based biopharma said Friday it is initiating the development pf TJM2 to treat cytokine storms in severe and critically
- 03/13/2020
|
136 Biggest Movers From Yesterday
- Gainers
Ranger Energy Services, Inc. (NYSE: RNGR) shares rose 44.8% to close at $4.46 on Thursday.
Ampco-Pittsburgh Corporation (NYSE: AP) shares surged 35.6% to close at $3.20...
- 03/13/2020
|
GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test
- GenMark Diagnostics, Inc shares are headed higher again following an update from the company regarding its COVID-19 diagnostics test.
- 03/11/2020
|
Parallax Health up 13% on planned coronavirus test
- Thinly traded nano cap Parallax Health Sciences (OTCPK:PRLX +13%) is, yet another, would-be player in the mad dash for a rapid screening test for COVID-19.Today, it announced that subsidiary Parallax
- 03/11/2020
|
GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test
- GenMark Diagnostics, Inc (NASDAQ: GNMK) shares are headed higher again following an update from the company regarding its COVID-19 diagnostics test.The company said it has submitted an Emergency Use Authorization, or EUA, to the FDA for its ePlex SARS-CoV-2 Test. Once the EUA is granted, the test could
- 03/11/2020
|
Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 11, 2020: TDOC, GNMK, HLT, MEET, AYTU
- Benzinga Pro's Stocks To Watch For Wednesday * Teladoc (TDOC) \- Shares of this virtual healthcare services provider were up about 5% Wednesday morning and up about 34% over the last month. As more events and schools are being cancelled, U.S. citizens are beginning to consider the possibility
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV
- 03/11/2020
|
Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers
- Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.
- 03/11/2020
|
Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers
- Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.
- 03/11/2020
|
Penny Stock Aytu Bioscience Skyrockets On COVID-19 Rapid Test Distribution Deal
- Shares of penny stock Aytu Bioscience Inc (NASDAQ: AYTU) were ripping higher Tuesday after the company said it signed a deal to distribute a COVID-19 test.
The...
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV
- 03/06/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
- 02/28/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
- 02/26/2020
|
35 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) stock increased by 38.4% to $3.10 during Tuesday's pre-market session. According to the most recent rating by H...
- 02/18/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- 02/14/2020
|
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- 02/13/2020
|
